Xin Lang Ji Jin·2025-09-14 11:46Group 1 - The core viewpoint of the news is that the innovative drug sector is experiencing a significant rebound, with both A-share and H-share innovative drug ETFs showing strong performance, indicating a bullish sentiment in the market [1][3][6] - The Hong Kong Stock Connect innovative drug ETF (520880) has seen a premium trading throughout the day, reflecting strong capital inflow, with over 160 million yuan invested during recent dips, marking eight consecutive days of capital accumulation [1][3] - Major stocks within the Hong Kong Stock Connect innovative drug ETF have collectively rebounded, with notable gains from companies such as Kangfang Biotech, which rose over 6%, and others like Innovent Biologics and CSPC Pharmaceutical, which increased by over 2% [3][4] Group 2 - The recent performance of the innovative drug ETF (520880) is attributed to a strategic adjustment in its underlying index, which now excludes CXO companies and focuses solely on innovative drug research and development, enhancing its ability to reflect industry trends accurately [5][6] - China's position in global new drug research has improved, with over 20% of new drugs in development worldwide originating from the country, highlighting the potential for continued growth in the innovative drug sector [6] - The low valuation of the Hong Kong innovative drug sector, combined with a high number of business development deals and ongoing interest in areas like small nucleic acids and oral GLP-1, suggests strong future growth potential [6]